Machine learning classification and regional differentiation of neuropathologically-confirmed Alzheimer's disease and

David K Park1, Allison B Constant2, Lawrence S Honig2,3,4

  • 1Department of Biomedical Engineering, Columbia University, New York, NY, USA.

Abstract

Insights

Machine learning accurately differentiates Alzheimer's disease (AD) with dementia with Lewy bodies (DLB) comorbidity from AD using MRI scans. This approach offers improved diagnostic potential for overlapping neurodegenerative diseases.

Area of Science:

  • Neuroimaging
  • Machine Learning
  • Neuropathology

Background:

  • Alzheimer's disease (AD) and dementia with Lewy bodies (DLB) frequently co-occur, suggesting synergistic interactions.
  • Neuropathological evidence supports a combined interplay between AD and DLB pathologies.
  • Differentiating comorbid AD/DLB from AD alone is clinically significant.

Purpose of the Study:

  • To determine if a single T1-weighted MRI scan can differentiate neuropathologically confirmed comorbid AD/DLB from AD controls.
  • To evaluate the efficacy of machine learning models in analyzing heterogeneously acquired neuroimaging data.
  • To assess the potential of neuroimaging biomarkers for diagnosing co-occurring neurodegenerative diseases.

Main Methods:

  • Structural neuroimaging data from two groups (AD with and without DLB pathology) were analyzed.
  • Convolutional neural networks (CNNs) were trained across different dimensions using a triple-ensemble strategy.
  • Voxel-wise statistical analyses were conducted alongside CNN-based classification.

Main Results:

  • CNNs achieved 0.820 classification accuracy and 0.79 f1 score in identifying comorbid DLB/AD from AD patients.
  • Prediction accuracy improved closer to the date of death and outperformed clinical baseline diagnosis.
  • Differential patterns of gray matter preservation and occipital lobe atrophy were observed in DLB/AD compared to AD.

Conclusions:

  • Machine learning effectively utilizes diverse neuroimaging data for differentiating neurodegenerative diseases with neuropathological confirmation.
  • The developed frameworks can be extended to other co-occurring diseases.
  • This approach shows potential for single-scan diagnostic utility in clinical settings for already acquired scans.

Related Concept Videos

Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Neural Regulation01:37

Neural Regulation

Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...